Driving the expansion of mRNA into the therapeutic sphere

The advanced therapies industry is heavily engaged in capitalizing upon the extensive ‘proof of concept’ gained through the success of mRNA-based COVID-19 vaccines. Novel therapeutic applications in major disease areas, including oncology, continue to show promise in preclinical and early clinical studies, yet challenges remain.

Here, a panel of thought-leaders from the mRNA field will consider the ever-expanding reach of mRNA technology, exploring at a high level how and where it will impact the advanced therapies space moving forward. The panel will then dive deeper into specific trends, issues, and innovations in mRNA processing (particularly downstream) and analytical development, discussing key areas for improvement and corresponding solutions.

Attend this webinar for:

• Expert analysis of recent R&D trends and progress pointing to how and where mRNA technology will have its next major impact in therapeutic application
• Assessment of remaining challenges in mRNA processing and supply chain
• Insights into the utility of new and emerging downstream purification and analytical technologies, and their potential to improve both the safety profile and efficacy of tomorrow’s mRNA therapeutics

Alejandro Becerra

Principal Applications Scientist and Global Purification Technical Lead, Thermo Fisher Scientific

Dr. Alejandro Becerra is a Principal Applications Scientist and Global Purification Technical Lead. Alejandro has over 14 years of experience in downstream processing and customer support having worked as Purification Team Manager and other bioprocess engineering roles prior to joining Thermo Fisher Scientific in 2018. Dr. Becerra is a subject matter expert in preparative chromatography with expertise in the development, optimization and scale-up of antibody, recombinant protein and viral vector purification processes. Alejandro holds a Ph.D. in Chemical Engineering from Cornell University.

Andreas Kuhn

SVP RNA Biochemistry & Manufacturing, BioNTech

Metin Kurtoglu

Chief GMP Manufacturing and Chief Medical Officer, Cartesian Therapeutics

Metin Kurtoglu, MD, PhD, is a medical oncologist board certified in internal medicine. Dr
Kurtoglu’s clinical and basic science research career spans over 20 years and has focused
on developing novel targets for drug-resistant cancer cells and cancer stem cells, including
multiple myeloma. He has also been an investigator in various cancer immunotherapy trials.
Cartesian Therapeutics is pioneering RNA cell therapies in and beyond oncology, with three
assets in clinical trials for autoimmune, oncologic and respiratory disorders. The investigational
therapies are manufactured at Cartesian’s cGMP manufacturing facility.